Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Third Rock Leads $30 Mil. Series B For CytomX

This article was originally published in The Pink Sheet Daily

Executive Summary

The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.

You may also be interested in...

Bristol Signs Two Cancer Immunotherapy Partners With Eye On Combos

Bristol will pay $50 million upfront to use CytomX’s Probody platform for up to four cancer immunotherapy targets. The company also partnered with InCyte to study its PD-1 inhibitor nivolumab with Incyte’s oral indoleamine dioxygenase-1 inhibitor.

CytomX’s Approach To Antibody-Drug Conjugates Earns Deal With Pfizer

The privately held California biotech calls its ADC technology Probody Drug Conjugates and claims it can create antibodies that will activate in a tumor’s micro-environment, while remaining dormant in healthy tissue. Pfizer is paying $25 million divided between upfront cash and preclinical milestones for a licensing deal around CytomX’s Probody Platform technology.

Big Pharma's Appetite for Biologics Platforms Fuels New Company Creation

With the industry on the cusp of a "me-better" era in biotherapies, Big Pharma has more incentive than ever to invest in novel platforms that can build better biologics. Start-Up profiles ArGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts